RTI Biologics Inc. (RTI) (Nasdaq: RTIX), a leading processor of orthopedic and other biologic implants, in response to inquiries regarding Medtronic's announced acquisition of Osteotech stated today that the relationship between Medtronic and RTI Biologics continues to be strong, with no changes near-term.
“Both companies have taken several steps over the years to continuously improve our relationship, and we have been assured that Medtronic will continue down that path with RTI. At this time we expect to continue to meet Medtronic's spinal allograft needs with high-quality, BioCleanse®-sterilized biologic implants.”
"We have received confirmation from Medtronic that our relationship is business as usual and they remain supportive of our current agreement, which runs through June 2014," said Brian K. Hutchison, RTI chairman and CEO. "Both companies have taken several steps over the years to continuously improve our relationship, and we have been assured that Medtronic will continue down that path with RTI. At this time we expect to continue to meet Medtronic's spinal allograft needs with high-quality, BioCleanse®-sterilized biologic implants."
Many people unaware that knee and groin pain could signal hip problems